Skip to main content
Lipocine Inc. logo

Lipocine Inc. — Investor Relations & Filings

Ticker · LPCN ISIN · US53630X1046 LEI · 549300RXPEQXOJXVBI10 US Manufacturing
Open in API
Filings indexed 788 across all filing types
Latest filing 2015-03-06 Investor Presentation
Country US United States of America
Listing US LPCN

About Lipocine Inc.

https://www.lipocine.com/

Lipocine Inc. is a clinical-stage biopharmaceutical company that develops treatments for metabolic, endocrine, and central nervous system disorders. The company leverages its proprietary Lip'ral drug delivery technology to enhance the oral absorption of water-insoluble drugs, aiming to improve patient compliance and therapeutic outcomes. Its portfolio includes TLANDO®, an FDA-approved oral testosterone replacement therapy. Lipocine's development pipeline features candidates for conditions such as non-alcoholic steatohepatitis (NASH), postpartum depression, obesity, and prevention of preterm birth. The company's strategy often involves using the 505(b)(2) regulatory pathway to develop improved formulations of established drugs.

Recent filings

Filing Released Lang Actions
CURRENT REPORT
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 6, 2015. It announces that the company will be presenting at the 27th Annual Roth Conference and attaches presentation materials as exhibits. The content is primarily about investor presentations and does not contain financial statements or detailed financial analysis. The document length is short (2329 characters) and it mainly serves as an announcement of presentations rather than the presentations themselves or a full report. Therefore, the most appropriate classification is Investor Presentation (IP).
2015-03-06 English
CURRENT REPORT
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 2, 2015. It announces that the company will be presenting at a healthcare conference and attaches presentation materials as exhibits. The text does not contain financial statements or detailed financial analysis but rather refers to presentations to be used at an investor conference. The document length is 2322 characters, which is relatively short and consistent with an announcement rather than a full report. According to the filing definitions, presentations for investors focusing on financials, strategy, and market position are classified as Investor Presentation (IP). Therefore, this document is best classified as an Investor Presentation (IP).
2015-03-02 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K, which is a current report filed with the SEC to announce specific events or disclosures. It references a press release about clinical data presentation at a meeting, filed as an exhibit. The document is short (2325 characters) and primarily serves as an announcement of an event and related press release, not a full financial report or detailed filing. It does not contain financial statements or detailed analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2015-02-27 English
SC 13G
Major Shareholding Notification
2015-02-13 English
SC 13G/A
Major Shareholding Notification
2015-02-12 English
LPCN 12.31.14
Major Shareholding Notification
2015-02-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.